South African HIV ART Guidelines Practice Quiz (40 questions)

All questions and answers

1. Which outcome best captures the principal goal of antiretroviral therapy (ART)?

Prevent new HIV infections without addressing illness in people living with HIV
Achieve and maintain viral suppression while improving health and quality of life
Provide treatment according to disease stage to improve access to care
Reduce HIV-related illness while leaving viral suppression as a secondary concern

Achieve and maintain viral suppression while improving health and quality of life

Explanation

ART aims to attain and maintain viral suppression while preventing new infections and reducing morbidity and mortality, thereby improving life expectancy and quality of life. Preventing transmission alone omits the individual health goals, and disease stage does not define eligibility.

2. A person living with HIV has a high CD4 count and no advanced clinical symptoms; how should their eligibility for ART be assessed?

The person becomes eligible if the CD4 count falls below a treatment threshold
The person is eligible regardless of CD4 count or clinical stage
The person becomes eligible after advanced clinical disease develops
The person is eligible only if they meet an age-based treatment criterion

The person is eligible regardless of CD4 count or clinical stage

Explanation

All people living with HIV are eligible for ART, independent of age, CD4 count, or clinical stage. A CD4 threshold or advanced disease requirement incorrectly makes eligibility conditional.

3. A newly diagnosed person living with HIV has no contraindication to ART and is ready to begin; what initiation timeframe is recommended?

Start within 30 days, with same-day initiation not considered
Start on the same day in every case, regardless of circumstances
Start within 7 days, and on the same day if possible
Wait at least 2 weeks before starting

Start within 7 days, and on the same day if possible

Explanation

In the absence of contraindications, ART should begin within 7 days and, if possible, on the same day. A routine two-week or 30-day delay exceeds the recommended timeframe, while same-day initiation is encouraged when possible rather than mandated in every situation.

4. A person with HIV has cough, night sweats, and recent weight loss but has not yet been evaluated for TB; what should be done before deciding on ART initiation?

Defer ART even if the investigation excludes TB
Start TB preventive therapy before assessing for active TB
Investigate for TB, then use the result to guide ART timing
Start ART immediately and investigate for TB afterward

Investigate for TB, then use the result to guide ART timing

Explanation

Cough, night sweats, fever, or recent weight loss call for TB investigation before ART. If TB is excluded, start ART and consider preventive therapy after checking for contraindications; confirmed TB instead requires TB treatment and ART timing based on infection site and CD4 count.

5. A client with non-neurological drug-sensitive TB is tolerating TB treatment, symptoms are improving, and the CD4 count is 38 cells/µL; when should ART be started?

Before TB treatment begins
8 weeks after TB treatment begins
Within 2 weeks after TB treatment begins
After 4–6 weeks of TB treatment

Within 2 weeks after TB treatment begins

Explanation

For non-neurological drug-sensitive TB, a CD4 count below 50 cells/µL calls for ART within 2 weeks of starting TB treatment when symptoms are improving and treatment is tolerated. The 8-week schedule applies when the CD4 count is at least 50 cells/µL.

6. A client is ready to start ART today. Baseline investigations have been performed, but their results are pending; there is no clinical evidence of TB, meningitis, or renal disease. What is appropriate?

Wait until every baseline result is available
Start ART only after repeating the investigations
Defer ART until a TB assessment is completed
Start ART today while awaiting the results

Start ART today while awaiting the results

Explanation

Baseline investigations should be performed before ART, but their results need not be available for same-day initiation when there is no clinical evidence of TB, meningitis, or renal disease. Waiting for all results confuses performing tests with having their results; repeating tests is not required by this rule; and a TB assessment has already found no clinical evidence of TB.

7. For a 12-year-old who is 150 cm tall with a serum creatinine of 75 µmol/L, which eGFR estimate and TDF decision follow the age-specific rule?

40 mL/min/1.73 m²; TDF is not acceptable below 80
50 mL/min/1.73 m²; TDF is acceptable above 50
80 mL/min/1.73 m²; TDF is not acceptable because the estimate is not above 80
80 mL/min/1.73 m²; TDF is acceptable at or above 80

80 mL/min/1.73 m²; TDF is not acceptable because the estimate is not above 80

Explanation

For ages 10 to under 16, eGFR is 150×4075=80 mL/min/1.73 m2\frac{150\times40}{75}=80\ \text{mL/min/1.73 m}^2. TDF is acceptable only when the estimate is above 80, so a result of exactly 80 does not meet the threshold; the adult MDRD cutoff is for clients aged at least 16.

8. A 17-year-old has an MDRD-calculated eGFR of 54 mL/min/1.73 m². Under the age-specific rule, is TDF use acceptable?

Yes, because serum creatinine is below 85 µmol/L
Yes, because the MDRD eGFR is above 50
No, because adolescent TDF requires eGFR above 80
No, because adolescent TDF requires eGFR above 60

Yes, because the MDRD eGFR is above 50

Explanation

For adolescents aged at least 16 years, TDF is acceptable when MDRD-calculated eGFR is above 50 mL/min/1.73 m², and 54 meets that criterion. The above-80 threshold applies to ages 10 to under 16, while the serum-creatinine threshold applies to pregnant women.

9. An HIV-positive infant is 8 months old, with a high CD4 percentage and no advanced clinical disease. What does the cotrimoxazole preventive therapy rule indicate?

Therapy is indicated only if the CD4 percentage falls
Therapy is indicated only if the clinical stage worsens
Cotrimoxazole preventive therapy is indicated
Cotrimoxazole preventive therapy is not indicated

Cotrimoxazole preventive therapy is indicated

Explanation

Cotrimoxazole preventive therapy is indicated for every HIV-positive infant under 1 year, regardless of CD4 percentage or clinical stage. Requiring a low CD4 percentage or advanced disease adds conditions that the infant rule does not impose; the age criterion is under 1 year.

10. An asymptomatic client is being assessed for TB preventive therapy, and the GeneXpert result is still pending. Active TB has been ruled out clinically and by available testing. What is an appropriate approach?

Begin both treatments before assessing whether active TB is present
Start TB preventive therapy and ART on the same day without waiting for the GeneXpert result
Wait for the GeneXpert result before starting TB preventive therapy, but begin ART now
Start TB preventive therapy now, but defer ART until the preventive course is finished

Start TB preventive therapy and ART on the same day without waiting for the GeneXpert result

Explanation

For an asymptomatic client, TB preventive therapy need not wait for an outstanding GeneXpert result, and it may begin on the same day as ART once active TB has been ruled out. Waiting for every result delays therapy, starting without excluding active TB skips an essential assessment, and deferring ART until the preventive course ends is not required.

11. A non-pregnant adult with no active liver disease, alcohol abuse, or known isoniazid hypersensitivity is starting TB preventive therapy. Which regimen is appropriate?

Isoniazid 300 mg daily for 6 months with pyridoxine 25 mg daily
Isoniazid 10 mg/kg daily for 6 months with pyridoxine daily
Isoniazid 300 mg daily for 12 months with pyridoxine 25 mg daily
Isoniazid 25 mg daily for 12 months with pyridoxine 300 mg daily

Isoniazid 300 mg daily for 12 months with pyridoxine 25 mg daily

Explanation

For non-pregnant adults and adolescents aged at least 15 years, the regimen is isoniazid 300 mg daily for 12 months plus pyridoxine 25 mg daily. The 6-month, weight-based regimen is for children younger than 15; the other alternatives use the wrong duration or reverse the medication doses.

12. A 12-year-old child living with HIV weighs 20 kg and has no symptoms of TB. Which TB preventive therapy regimen fits the age-based recommendation?

Isoniazid 300 mg daily for 12 months, with pyridoxine 25 mg daily
Isoniazid 200 mg daily for 12 months, with daily pyridoxine
Isoniazid 200 mg daily for 6 months, with daily pyridoxine
Isoniazid 200 mg daily for 6 months, without pyridoxine

Isoniazid 200 mg daily for 6 months, with daily pyridoxine

Explanation

For a child younger than 15 years, isoniazid is 10 mg/kg/day for 6 months, up to 300 mg daily, with daily pyridoxine; at 20 kg, the dose is 200 mg daily. The 300 mg, 12-month regimen is for older clients, while the other choices use the wrong duration or omit pyridoxine.

13. Which combination best describes dolutegravir's clinical profile?

An integrase inhibitor associated with rapid viral suppression, a low resistance barrier, and frequent interactions
An integrase inhibitor associated with rapid viral suppression, a high resistance barrier, and good tolerability
An integrase inhibitor associated with slow viral suppression, a high resistance barrier, and substantial side effects
A reverse-transcriptase inhibitor associated with rapid viral suppression, a high resistance barrier, and good tolerability

An integrase inhibitor associated with rapid viral suppression, a high resistance barrier, and good tolerability

Explanation

Dolutegravir is an integrase inhibitor that provides rapid viral suppression, has a high genetic barrier to resistance, and is generally well tolerated with minimal side effects and drug interactions. The alternatives misidentify its drug class or reverse key features of its resistance barrier, interactions, or tolerability.

14. A 16-year-old client weighs 32 kg and is being considered for the adult TLD fixed-dose combination. Which formulation and eligibility assessment are correct?

Abacavir 600 mg, lamivudine 300 mg, and DTG 50 mg; eligible by age and weight
TDF 300 mg, lamivudine 300 mg, and DTG 300 mg; eligible by age and weight
TDF 300 mg, lamivudine 300 mg, and DTG 50 mg; eligible by age and weight
TDF 300 mg, lamivudine 300 mg, and DTG 50 mg; below the weight threshold

TDF 300 mg, lamivudine 300 mg, and DTG 50 mg; eligible by age and weight

Explanation

The adult TLD combination contains tenofovir 300 mg, lamivudine 300 mg, and dolutegravir 50 mg, and is prescribed from 30 kg and 10 years of age. This client meets both criteria; the distractors either misjudge the threshold, substitute ALD ingredients, or give the wrong dolutegravir dose.

15. A client taking TLD begins rifampicin-containing TB treatment. What adjustment to dolutegravir is recommended?

Continue TLD and add DTG 50 mg 24 hours after the fixed-dose combination
Continue TLD and add DTG 50 mg 12 hours after the fixed-dose combination
Replace TLD with DTG 50 mg every 12 hours during rifampicin treatment
Continue TLD without an extra DTG dose during rifampicin treatment

Continue TLD and add DTG 50 mg 12 hours after the fixed-dose combination

Explanation

Rifampicin-containing TB treatment requires increasing dolutegravir to 50 mg every 12 hours; for a client taking TLD, add DTG 50 mg 12 hours after the fixed-dose combination. A 24-hour interval is incorrect, no additional dose fails to account for the interaction, and replacing TLD does not follow the stated adjustment.

16. Two clients are taking DTG-containing ART. One has never failed a previous regimen, while the other has failed an earlier regimen. Which classification matches the clients, respectively?

TLD1 and TLD2
TLD1 and TLD1
TLD2 and TLD2
TLD2 and TLD1

TLD1 and TLD2

Explanation

TLD1 refers to clients on a DTG-containing regimen with no previous regimen failure, while TLD2 refers to those with an earlier failure. Reversing the categories confuses TLD1 with TLD2; assigning both TLD1 or both TLD2 ignores the difference in prior failure history.

17. A client returns to care after 120 days away and previously received third-line ART. What regimen should be restarted?

The previous third-line regimen
A first-line regimen
A DTG-containing regimen
A newly selected regimen

The previous third-line regimen

Explanation

A client returning after more than 90 days who was previously lost to follow-up on third-line therapy should restart the third-line regimen. The DTG restart rule applies to specified prior regimens such as TDF or TLD, while the treatment gap alone does not call for a first-line or newly selected regimen.

18. At a routine ART visit, a client has not raised contraception. What should the care team do about family planning?

Select a contraceptive method on the client’s behalf
Defer the discussion until the client requests a method
Limit the discussion to the ART initiation visit
Discuss family planning and offer options through patient-centred services

Discuss family planning and offer options through patient-centred services

Explanation

Family planning and contraception should be discussed at every clinical interaction, with options offered through integrated, patient-centred services and informed voluntary choice. Waiting for a request or limiting counselling to initiation misses the every-interaction principle, and choosing a method for the client conflicts with voluntary choice.

19. A woman receiving ART says she wants to become pregnant. Before she tries to conceive, what should counselling help her achieve?

No opportunistic infections without first establishing ART
Established ART, viral suppression, and no current opportunistic infections
Established ART and a contraceptive method during attempts to conceive
Viral suppression without checking for opportunistic infections

Established ART, viral suppression, and no current opportunistic infections

Explanation

Before trying to conceive, she should be counselled to establish ART, attain viral suppression, and have no current opportunistic infections. Contraception is not the preparation goal in this situation, and ART or viral suppression alone omits one or more required conditions.

20. Which group of antiretroviral regimens has significant interactions with rifampicin-containing TB treatment?

All paediatric ART regimens and adult or adolescent regimens containing dolutegravir
Adult and adolescent regimens containing efavirenz, but not paediatric regimens
All adult ART regimens and paediatric regimens containing efavirenz
Only regimens containing lopinavir/ritonavir, regardless of age

All paediatric ART regimens and adult or adolescent regimens containing dolutegravir

Explanation

Rifampicin has significant interactions with every paediatric ART regimen and with adult or adolescent regimens that contain dolutegravir. The other choices either broaden or narrow the affected groups incorrectly.

21. An adult taking rifampicin can swallow whole LPV/r tablets. How should the LPV/r tablets be administered?

Give double-dose tablets after crushing them and mixing them with soft food
Give the standard tablet dose and add ritonavir powder twice daily
Give double-dose tablets whole, without crushing, breaking, or chewing them
Give the standard dose of tablets whole, without crushing, breaking, or chewing them

Give double-dose tablets whole, without crushing, breaking, or chewing them

Explanation

With rifampicin, adults, adolescents, and children able to swallow whole LPV/r tablets should receive double-dose tablets, which must remain intact. A standard tablet dose misses the adjustment, crushing is not allowed, and ritonavir powder is the approach for specified liquid, pellet, or 4-in-1 formulations.

22. A child taking LPV/r solution begins rifampicin, and ritonavir powder is available. What dosing approach should be used?

Double the LPV/r solution dose and omit ritonavir powder
Switch to double-dose LPV/r tablets and crush them into the solution
Reduce the LPV/r solution dose and add ritonavir powder once daily
Maintain the standard LPV/r dose and add ritonavir powder twice daily

Maintain the standard LPV/r dose and add ritonavir powder twice daily

Explanation

For LPV/r solution, pellets, or 4-in-1 ABC/3TC/LPV/r with rifampicin, the standard LPV/r dose is maintained and ritonavir powder is added twice daily. Doubling or reducing the LPV/r dose confuses this approach with other dosing strategies, and the tablet rule does not apply to solution.

23. An adult taking dolutegravir starts rifampicin-based TB treatment. What dolutegravir schedule is indicated?

25 mg every 12 hours
50 mg once daily
100 mg every 24 hours
50 mg every 12 hours

50 mg every 12 hours

Explanation

Adults and adolescents taking rifampicin should increase dolutegravir dosing to 50 mg every 12 hours. Once-daily dosing does not make the required frequency adjustment, while the other schedules use an incorrect dose or timing.

24. An adult who is ART-treatment-naive starts TB treatment and has not yet begun ART. Which initiation plan is appropriate?

Start efavirenz as the required choice, or delay dolutegravir until TB treatment ends
Continue without ART during TB treatment, then choose either regimen afterward
Start dolutegravir without boosting, or efavirenz regardless of treatment history
Start dolutegravir with boosting as indicated, or efavirenz because the adult is treatment-naive

Start dolutegravir with boosting as indicated, or efavirenz because the adult is treatment-naive

Explanation

Adults not yet on ART when TB treatment starts may initiate dolutegravir with boosting as indicated, or efavirenz if they are ART-treatment-naive. Omitting indicated boosting, removing the treatment-naive condition for efavirenz, or deferring ART changes the stated rule.

25. A clinic has completed a patient's TB investigations and viral-load test. When should the results be reviewed?

At the end of TB treatment, before deciding on follow-up
No earlier than 7 days after the tests are completed
Two weeks after TB treatment is completed
Within 5–7 days, or sooner if possible

Within 5–7 days, or sooner if possible

Explanation

TB investigation and viral-load results should be reviewed within 5–7 days, or sooner if possible. The two-week interval concerns a regimen switch after TB treatment, while waiting until treatment ends or imposing a minimum delay would postpone review unnecessarily.

26. A client enrolled in RPCs is diagnosed with TB and has a suppressed viral load. What follow-up pathway applies?

Return to regular clinician-managed care and reassess RPC eligibility after TB treatment is completed
Reassess for RPC enrolment immediately while TB treatment is ongoing
Remain in RPCs because the viral load is suppressed and reassess at the next routine visit
Return to clinician-managed care only if viral load reaches 50 copies/mL

Return to regular clinician-managed care and reassess RPC eligibility after TB treatment is completed

Explanation

A TB diagnosis triggers a return to regular clinician-managed care, even when viral load is suppressed; RPC enrolment is reassessed after TB treatment is completed. Treating suppression as overriding TB confuses the separate triggers, and 50 copies/mL is the viral-load threshold that independently prompts return to clinician-managed care.

27. A patient is struggling to take treatment consistently, but persistent non-adherence has not been established. Which enhanced adherence counselling session is appropriate now?

The second session
A follow-up session after persistent non-adherence
The initial session
A session reserved for persistent non-adherence

The initial session

Explanation

The initial session is intended for patients struggling with adherence; the second session is for those who remain persistently non-adherent. The other answers incorrectly assign the second-stage counselling to a patient who has not yet reached that stage.

28. During a patient's first enhanced adherence counselling session, the counsellor has explained the session's purpose and explored possible reasons for an abnormal result. What should the counsellor also do as part of this session?

Record barriers and leave strategies and planning for another visit
Change the treatment regimen and arrange a later adherence review
Address barriers and strategies, then develop or update a plan together
Confirm persistent non-adherence before creating an adherence plan

Address barriers and strategies, then develop or update a plan together

Explanation

The initial session includes addressing adherence barriers, discussing strategies to overcome them, and updating or developing an adherence plan with the patient. Changing the regimen, waiting for persistent non-adherence, or postponing strategy and plan development does not capture this session's stated work.

29. A clinician is conducting a basic mental-health screen. Which set of areas should the clinician assess?

Appearance, memory, and daily functioning
Mood, daily functioning, and treatment history
Thoughts, sleep, and treatment adherence
Appearance, mood, thoughts, and cognition

Appearance, mood, thoughts, and cognition

Explanation

Basic screening covers appearance, mood, thoughts, and cognition, including concentration, memory, unusual experiences, and negative thoughts. The other choices omit key screening domains or replace them with other assessment concerns.

30. A patient reports persistent negative thoughts and also describes hearing voices that others do not hear. Which interpretation best distinguishes these findings?

Negative thoughts may suggest psychosis; hearing voices may suggest depression
Both findings may suggest depression rather than psychosis
Both findings may suggest psychosis rather than depression
Negative thoughts may suggest depression; hearing voices may suggest psychosis

Negative thoughts may suggest depression; hearing voices may suggest psychosis

Explanation

Negative thoughts can suggest depression, whereas unusual experiences such as hearing voices can raise suspicion of psychosis. Reversing these associations or treating both as signs of just one condition confuses the distinction.

31. During an assessment, a patient says they may harm themselves and reports seeing things that other people do not see. What response is indicated?

Wait for a confirmed diagnosis before referring
Complete a routine assessment before considering referral
Refer directly for psychiatric support
Arrange routine follow-up and reassess the reported experiences

Refer directly for psychiatric support

Explanation

Risk of harm to self and seeing things others do not are each indications for direct referral for psychiatric support. Deferring referral for routine screening, a confirmed diagnosis, or ordinary follow-up overlooks these referral triggers.

32. A patient taking abacavir develops a hypersensitivity reaction. What should happen to abacavir treatment?

Abacavir should be restarted at a lower dose after recovery.
Abacavir should be paused until the symptoms resolve.
Abacavir should be continued while symptoms are monitored.
Abacavir should be stopped permanently.

Abacavir should be stopped permanently.

Explanation

An abacavir hypersensitivity reaction requires permanent discontinuation. A temporary pause, continued treatment with monitoring, or restarting at a lower dose does not follow this rule; early symptoms should be discussed with a clinician rather than prompting patients to stop treatment themselves.

33. A child with haemoglobin of 7.6 g/dL is being considered for zidovudine. What is the appropriate prescribing approach?

Avoid zidovudine or use it cautiously because it can suppress bone marrow.
Avoid zidovudine because low haemoglobin indicates impaired kidney function.
Use zidovudine without added caution because the child is not a neonate.
Use zidovudine cautiously only if the child also has a viral infection.

Avoid zidovudine or use it cautiously because it can suppress bone marrow.

Explanation

Zidovudine can suppress bone marrow, so it should be avoided or used cautiously in children with haemoglobin below 8 g/dL. The concern is not kidney toxicity, and the caution applies to children as well as neonates.

34. An adolescent is 12 years old and weighs 36 kg. Renal function is checked before tenofovir is prescribed. Which follow-up schedule is appropriate for creatinine and eGFR?

Assess at month 10, then repeat every 12 months.
Assess at months 3 and 10, then stop routine renal monitoring.
Assess every month during the first year, then every 12 months.
Assess at months 3 and 10, then repeat every 12 months.

Assess at months 3 and 10, then repeat every 12 months.

Explanation

For an eligible adolescent, renal function is checked before tenofovir, with creatinine and eGFR assessed at months 3 and 10 and every 12 months thereafter. Omitting either early check or subsequent annual testing misses part of the recommended schedule.

35. A clinician is converting a patient's dolutegravir dose from dispersible tablets to film-coated tablets. Which dose equivalence should be used?

30 mg dispersible corresponds to 30 mg film-coated.
30 mg dispersible corresponds to 50 mg film-coated.
25 mg dispersible corresponds to 50 mg film-coated.
50 mg dispersible corresponds to 30 mg film-coated.

30 mg dispersible corresponds to 50 mg film-coated.

Explanation

Dolutegravir dispersible and film-coated tablets are not bioequivalent; 30 mg of dispersible tablet corresponds to 50 mg of film-coated tablet. Equal milligram doses therefore cannot be assumed to provide the stated equivalence.

36. A child with normal cognition and maturity is 12 years old and has not yet had a sexual debut. When is full HIV-status disclosure ideally planned?

After age 14, once sexual debut has occurred.
Between ages 10 and 14, before sexual debut.
Between ages 10 and 14, after sexual debut.
Between ages 5 and 9, before sexual debut.

Between ages 10 and 14, before sexual debut.

Explanation

For a child with normal cognition and maturity, full disclosure is ideally made between ages 10 and 14, before sexual debut. Ages 5–9 are associated with partial disclosure, not the target for full disclosure.

37. A care team is planning how to tell a child about their HIV status. Which approach best reflects the recommended disclosure process?

Begin with full disclosure, then move to partial disclosure and post-disclosure support.
Provide partial disclosure, then end the process once full disclosure is completed.
Provide post-disclosure support first, then partial disclosure and full disclosure.
Progress gradually from partial disclosure to full disclosure, followed by post-disclosure support.

Progress gradually from partial disclosure to full disclosure, followed by post-disclosure support.

Explanation

Disclosure is ideally a gradual process over many years, progressing from partial disclosure to full disclosure, then post-disclosure and ongoing support. Starting with full disclosure reverses the intended progression, while ending support at the point of full disclosure omits later follow-up.

38. A clinic notices an unexpected reaction after a patient takes a medicine, an adverse event after an immunisation, and a suspected quality defect in a product. What should the healthcare team do?

Report the product-quality concern and medicine reaction to the immunisation programme
Report only concerns confirmed to have caused serious harm
Report all three concerns to the SAHPRA pharmacovigilance office
Report the medicine reaction and immunisation event to the product supplier

Report all three concerns to the SAHPRA pharmacovigilance office

Explanation

Healthcare professionals and consumers are urged to report adverse drug reactions, events following immunisation, and product-quality concerns to the SAHPRA pharmacovigilance office. Restricting reports to medicine reactions, omitting quality concerns, or requiring confirmed serious harm each narrows the reporting scope incorrectly.

39. Which set consists entirely of listed ways to submit an adverse drug reaction report?

Email to [email protected], a telephone hotline, and the MedSafety smartphone application
Email to [email protected], the WHO online e-reporting portal, and the MedSafety smartphone application
Email to a general clinic inbox, the WHO online e-reporting portal, and a paper form
Email to a product supplier, the WHO online e-reporting portal, and the MedSafety smartphone application

Email to [email protected], the WHO online e-reporting portal, and the MedSafety smartphone application

Explanation

The listed reporting methods are email to [email protected], the WHO online e-reporting portal, and the MedSafety smartphone application. A supplier, hotline, clinic inbox, or paper form is not one of the specified methods.

40. An adult has a BMI of 27.4 kg/m². Which weight category applies?

Normal weight
Obesity
Overweight
Underweight

Overweight

Explanation

A BMI from 25 to below 30 kg/m² indicates overweight, so 27.4 falls in that range. Obesity begins at 30, normal weight is below 25, and underweight is below 18.5.

Study with flashcards

Lock in the answers with 92 flashcards on South African HIV ART Guidelines.

What is the principal goal of ART?

To attain and maintain viral suppression.

What does viral suppression through ART help prevent?

New HIV infections.

How does ART affect life expectancy?

It increases life expectancy.

See the flashcards →

Read the study guide

Go over the full study guide for South African HIV ART Guidelines.

Read the study guide →

Related classes

Make your own practice quizzes

Upload your class notes and Revizly writes a practice quiz with explained answers in about a minute.

Quiz maker